Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal assures diversity of supply to meet future long-term plans for expanded availability of the gene therapy Two additional state-of-the-art manufacturing facilities for ADSTILADRIN are near completion in Finland and the U.S. Parsippany, NJ and King of Prussia, PA, U.S.– April 18, […]

Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies to evaluate ADSTILADRIN demonstrate Ferring’s commitment to improve outcomes for patients across the spectrum of urothelial cancers Research will enlarge the body of evidence for ADSTILADRIN, the first and only FDA-approved intravesical non-replicating gene therapy for NMIBC Parsippany, NJ – April […]

A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in a registrational Phase 3 clinical trial An integrated safety analysis showed SI-6603 was well tolerated and could offer a potential treatment option for pain relief from Lumbar Disc Herniation (LDH) A real-world analysis of current treatments for LDH showed a gap […]